TARSUS PHARMACEUTICALS INC (TARS)
Health Care · Ophthalmic therapeutics / antiparasitic biopharmaceuticals · NASDAQ
Tarsus Pharmaceuticals commercializes XDEMVY, the first FDA-approved treatment for Demodex blepharitis, with a pipeline of lotilaner-based therapies for ocular and infectious diseases.
What TARSUS PHARMACEUTICALS INC does
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for eye care and infectious diseases. The company's lead product is XDEMVY (lotilaner ophthalmic solution), an FDA-approved treatment for Demodex blepharitis that launched in August 2023. The company is also developing TP-04, a gel formulation for ocular rosacea, and TP-05, an oral tablet for Lyme disease prophylaxis and malaria reduction.
Themes: ["Demodex blepharitis treatment","Eye care / ophthalmology","Antiparasitic therapeutics","Infectious disease prevention","Ocular rosacea","Meibomian Gland Disease (MGD)"]
Fundamentals
- Price$64.14 as of 2026-07-09 close
- Market cap$2.8B as of 2026-07-10
- 1-year return+70.6% as of 2026-07-09 close
- Net margin-9.0% as of 2026-07-10
- Gross margin+93.5% as of 2026-07-10
- ROE-14.2% as of 2026-07-10
- Debt / equity0.21 as of 2026-07-10
- Revenue growth (YoY)+129.0% as of 2026-07-10
- Revenue CAGR (3y)+159.5% SEC XBRL
- Beta0.51 as of 2026-07-10
Key risks (from latest filing)
["XDEMVY market acceptance and commercialization execution depend on achieving adequate reimbursement, payer coverage, and eye care professional/patient adoption for a newly approved treatment in a disease awareness phase","Pipeline candidates (TP-04, TP-05) face regulatory approval, clinical development, and competitive risks with no guarantee of success or commercial viability","Company is currently unprofitable with significant dependence on existing capital and follow-on funding to sustain operations and clinical development programs"]
Competitors & peers
- Bausch + Lomb (conventional eyelid hygiene and topical solutions for blepharitis)
- Allergan / AbbVie (eye care therapeutics)
- Akorn Pharmaceuticals (ophthalmology products)
- Verrica Pharmaceuticals (treatments for parasitic skin conditions)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.